PLRZ Stock — Polyrizon Ltd. Ordinary Shares

Polyrizon Ltd. Ordinary Shares (PLRZ)

Updated October 16, 2026.

PLRZ is a Stock. Its deepest 1-year drawdown was 55.0%.

Polyrizon Ltd. is an Israeli biotech company developing medical device hydrogels delivered as nasal sprays, including products designed to block allergens and viruses and to enable nasal delivery of pharmaceutical ingredients. The company's pipeline includes candidates for nasal allergies and influenza prevention. Distribution information is not available for this security.

PLRZ performance

Returns are updating. PLRZ's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 55.0%.

PLRZ key facts

Asset type

Stock

Asset class

Equity

Inception date

10/29/2024

Distribution frequency

None

Last close

$10.00 (as of 2026-10-16)

Market cap

$24,286,040

Average volume

19255.0

Payout ratio

0.0%

EPS

$-4.97

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PLRZ risks and drawbacks

The deepest 1-year drawdown on record here is 55.0%.

Who may consider PLRZ — and who may not

It is a weaker fit for investors who need monthly cash flow (PLRZ does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on PLRZ

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions